HTG Molecular Diagnostics (HTGM) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of HTG Molecular Diagnostics (NASDAQ:HTGM) from a hold rating to a buy rating in a research note published on Wednesday morning. They currently have $4.00 price objective on the medical research company’s stock.

According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

Several other equities analysts also recently weighed in on the company. HC Wainwright reissued a buy rating and set a $6.00 target price on shares of HTG Molecular Diagnostics in a research report on Wednesday, November 8th. ValuEngine raised HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity boosted their target price on HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $5.25.

HTG Molecular Diagnostics (NASDAQ HTGM) traded up $0.54 during trading hours on Wednesday, reaching $3.40. The company’s stock had a trading volume of 2,630,000 shares, compared to its average volume of 1,280,000. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25. The company has a market cap of $38.92 and a P/E ratio of -1.33.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings data on Tuesday, November 7th. The medical research company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.03. equities analysts forecast that HTG Molecular Diagnostics will post -1.92 earnings per share for the current fiscal year.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Granahan Investment Management Inc. MA increased its stake in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 488.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 416,608 shares of the medical research company’s stock after purchasing an additional 345,798 shares during the quarter. Granahan Investment Management Inc. MA owned 3.33% of HTG Molecular Diagnostics worth $708,000 at the end of the most recent quarter. Institutional investors own 15.15% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3144857/htg-molecular-diagnostics-htgm-rating-increased-to-buy-at-zacks-investment-research.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.